Primed Pharmaceuticals LLC v. Starr Indemnity & Liability Company

CourtDistrict Court, S.D. New York
DecidedJanuary 25, 2024
Docket1:21-cv-01025
StatusUnknown

This text of Primed Pharmaceuticals LLC v. Starr Indemnity & Liability Company (Primed Pharmaceuticals LLC v. Starr Indemnity & Liability Company) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Primed Pharmaceuticals LLC v. Starr Indemnity & Liability Company, (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK PRIMED PHARMACEUTICALS LLC, Plaintiff, -v- CIVIL ACTION NO. 21 Civ. 1025 (SLC)

STARR INDEMNITY & LIABILITY COMPANY, OPINION AND ORDER Defendant.

SARAH L. CAVE, United States Magistrate Judge.

I. INTRODUCTION Plaintiff PriMed Pharmaceuticals LLC (“PriMed”) brought this breach of contract and declaratory judgment action against Defendant Starr Indemnity & Liability Company (“Starr”) seeking damages and a declaration that Starr has a duty to defend and indemnify PriMed in connection with a pending trademark litigation. (ECF No. 1 ¶¶ 51–63 (the “Complaint”)). Following the Court’s Opinion and Order granting PriMed’s motion for summary judgment, see PriMed Pharms. LLC v. Starr Indem. & Liab. Co., No. 21 Civ. 1025 (SLC), 2023 WL 2537849 (S.D.N.Y. Mar. 16, 2023) (“PriMed I”), PriMed moved for monetary damages (ECF No. 119 (the “Damages Motion”)), which Starr opposes. (ECF No. 130 (the “Opposition”)). For the reasons set forth below, PriMed’s Damages Motion is DENIED WITHOUT PREJUDICE. II. BACKGROUND A. Background The Court incorporates by reference the factual and procedural background and defined

terms set forth in PriMed I, 2023 WL 2537849, at *1–5.1 The Court sets forth only those additional facts necessary to the Damages Motion. 1. The Abbott Litigation2 Business associates of PriMed’s President and Owner, Matthew Zeigler (“Zeigler”), told him that Richard S. Schurin (“Schurin”) of Stern & Schurin LLP (the “Firm”) “had special expertise

with regard to suits involving alleged infringement of products in the secondary wholesale market.” (ECF No. 123 ¶ 16). For example, the Firm, “an intellectual property boutique,” defended wholesalers in the trademark and trade dress litigation captioned Innovation Ventures, LLC v. Ultimate One Distribs. Corp., No. 12 Civ. 5354 (KAM) (E.D.N.Y.). (ECF No. 124 ¶¶ 2, 17). After speaking with Schurin and conducting “due diligence,” Zeigler retained the Firm to represent himself and PriMed in the Abbott Litigation. (ECF No. 123 ¶ 17). When Zeigler signed

an engagement letter with the Firm on November 29, 2015 (ECF No. 128-1 (the “First Engagement Letter”)), Schurin’s hourly billing rate was $550, while Steven Stern (“Stern”) billed at $550 and other attorneys at the Firm billed at $325. (ECF No. 123 ¶ 18; see ECF No. 124 ¶¶ 5, 7). Zeigler considered these rates “to be reasonable for the type of legal services that they were to provide and given the seriousness of the Abbott Litigation to [him]self and [his] business.” (ECF No. 123 ¶ 19). After Zeigler received the Firm’s invoice for services provided in

1 Internal citations and quotation marks are omitted from case citations unless otherwise indicated. 2 Abbott Lab’ys, et al. v. Adelphia Supply USA, et al., No. 15 Civ. 5826 (CBA) (LB) (E.D.N.Y.). December 2015, in the amount of $8,345, Zeigler became concerned about PriMed’s cash flow and negotiated with the Firm for PriMed to pay a monthly flat fee of $6,500. (Id. ¶¶ 20–24; see ECF No. 124 ¶¶ 9–10). The Firm’s invoices for services rendered between April 2016 and

December 2020 each state, “For Services Rendered in Abbott Litigation for [month]: $6,500.00,” but do not contain individual time entries and descriptions. (ECF No. 128-4 (the “Flat Fee Invoices”)). The Flat Fee Invoices, for which PriMed is seeking reimbursement from Starr in the Damages Motion, total $357,5003 (the “Claimed Damages”). (ECF Nos. 123 ¶ 33; 124 ¶ 12; 128-4). PriMed claims that it “has been damaged by Starr’s breach in having to pay for all of its

attorney[s’] fees [in the Abbott Litigation] without the support of its insurance.” (ECF No. 123 ¶ 37). Zeigler has “been personally involved” in PriMed’s defense in the Abbott Litigation “since the very beginning.” (ECF No. 123 ¶ 22). He had “very regular phone consultations” with attorneys at the Firm regarding the Abbott Litigation and the Firm’s invoices. (Id. ¶¶ 23–25). Schurin prepared Zeigler for and defended him at his deposition. (Id. ¶ 28). Following summary

judgment motions in the Abbott Litigation and the filing of this action, Zeigler and the Firm reached an agreement “to revert back to an hourly billing arrangement for the Abbott Litigation.” (Id. ¶ 31). That agreement, memorialized in a second engagement letter dated January 14, 2021 (the “Second Engagement Letter”), afforded PriMed “a two-month courtesy discount, saving Primed $13,000.” (Id. ¶ 31). The Claimed Damages account for this discount. (Id. ¶ 33). Since the execution of the Second Engagement Letter in January 2021, the Firm has not yet issued an

3 $6,500 (the monthly flat fee) multiplied by 57 (the number of months from April 2016 to December 2020, inclusive) minus $13,000 (a “two-month courtesy discount” (ECF Nos. 123 ¶ 33; 124 ¶ 12)) equals $357,500. invoice to PriMed “due to the small quantity of work performed in the Abbott Litigation.” (ECF No. 124 ¶ 13). a. The Firm’s Attorneys

Four attorneys at the Firm represented PriMed in the Abbott Litigation. (ECF No. 124 ¶¶ 17–21). Schurin was admitted to the New York bar in 1995, and since at least 2000 has focused on intellectual property litigation. (Id. ¶ 18). Stern was admitted to the New York bar in 2001 and the Patent bar in 2002, and has appeared in more than “100 federal cases involving intellectual property matters.” (Id. ¶ 19). Evgeny Krasnov was admitted to the New

York bar in 2014 and is now a partner at his own firm, “where he continues to practice intellectual property law.” (Id. ¶ 20). Michael Barer was admitted to the New York bar in 2014 and has “represented clients in all manner of trademark, trade dress, copyright and trade secret litigation.” (Id. ¶ 21). b. The Phases of the Abbott Litigation The Firm’s representation of PriMed covered five phases of the Abbott Litigation.

(ECF No. 124 ¶ 25). First, “Primed and other similarly situated wholesaler defendants” moved to dismiss certain of Abbott’s claims, which the Honorable Carol Bagley Amon granted in part on January 4, 2017 to the extent of dismissing Abbott’s RICO and unjust enrichment claims. (See id. ¶¶ 27–28). See Abbott Lab’ys. v. Adelphia Supply USA, No. 15 Civ. 5826 (CBA) (LB), 2017 WL 57802, at *1, 14 (E.D.N.Y. Jan. 4, 2017). Second, the Firm represented PriMed through fact and expert discovery between May 2016 and March 2018. (ECF No. 124 ¶¶ 29–36). Third,

the parties filed motions for summary judgment, which Judge Amon granted in part and denied in part, dismissing the fraud claims against PriMed and certain other wholesaler defendants, denying Abbott’s motion as to willful infringement against PriMed and others, and denying Abbott’s request for an award of damages, which was to be reserved for trial. (Id. ¶¶ 37–42). See Abbott Lab’ys v. Adelphia Supply USA, No. 15 Civ. 5826 (CBA) (LB), 2019 WL 5696148 (E.D.N.Y.

Sept. 30, 2019). Fourth, PriMed sought to distance itself from the sanctions imposed on one of its codefendants, whose damages inquest was severed from the damages trial involving PriMed and the other remaining wholesaler defendants. (ECF No. 124 ¶¶ 43–47). See Abbott Lab’ys v. Adelphia Supply USA, No. 15 Civ. 5826 (CBA) (LB), 2020 WL 7643213 (E.D.N.Y. Dec. 23, 2020). Fifth, the Firm has continued to represent PriMed in preparation for trial, which is scheduled for

May 2024, and in connection with settlement negotiations. (ECF No. 124 ¶¶ 48–50). See Abbott Lab’ys, et al. v. Adelphia Supply USA, et al., No. 15 Civ. 5826 (CBA) (LB), ECF min. entry Nov. 21, 2023)). The Firm also represented three other defendants in the Abbott Litigation: Adelphia Supply USA; Value Wholesale, Inc.; and Med-Plus, Inc., and their principals. (ECF No. 134 ¶ 4). 2. This Action

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hensley v. Eckerhart
461 U.S. 424 (Supreme Court, 1983)
Green v. City of New York
403 F. App'x 626 (Second Circuit, 2010)
Millea v. Metro-North Railroad
658 F.3d 154 (Second Circuit, 2011)
Sternberg v. Fletcher
143 F.3d 748 (Second Circuit, 1998)
Bienenfeld v. Calderon
531 F. App'x 158 (Second Circuit, 2013)
Bliven v. Hunt
579 F.3d 204 (Second Circuit, 2009)
United States & Fidelity Guaranty Co. v. Copfer
400 N.E.2d 298 (New York Court of Appeals, 1979)
Taco Bell Corp. v. Continental Casualty Co.
388 F.3d 1069 (Seventh Circuit, 2004)
Cowan v. Codelia
50 F. App'x 36 (Second Circuit, 2002)
Beazley Insurance Co. v. ACE American Insurance Co.
197 F. Supp. 3d 616 (S.D. New York, 2016)
Olin Corp. v. Insurance Co. of North America
218 F. Supp. 3d 212 (S.D. New York, 2016)
Columbus Mckinnon Corp. v. Travelers Indem. Co.
367 F. Supp. 3d 123 (S.D. Illinois, 2018)
United Parcel Service v. Lexington Insurance Group
983 F. Supp. 2d 258 (S.D. New York, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Primed Pharmaceuticals LLC v. Starr Indemnity & Liability Company, Counsel Stack Legal Research, https://law.counselstack.com/opinion/primed-pharmaceuticals-llc-v-starr-indemnity-liability-company-nysd-2024.